

Amendments to the claims:

1. (Canceled) Use of a compound chosen from at least one of manno- oligosaccharides, caseinoglycomacropeptides (CGMP), methyl manno- oligosaccharides, chito oligosaccharides, pectic oligosaccharides, galacto-oligosaccharides (GOS), curdlan (beta 1,3-glucan), sialyl- oligosaccharides, isomalto-oligosaccharides, oligogalacturonide, partially hydrolysed guar gum, gentio-oligosaccharides, arabino- oligosaccharides, pectin, lactose, lactulose, lactosucrose and long-chain isomalto-oligosaccharides for the manufacture of a nutritional or pharmaceutical composition for the inhibition of pathogen adhesion to mammalian cells, and/or for preventing, reducing or inhibiting the invasion and infection of mammalian cells by pathogen, in particular mammalian gut and/or intestinal epithelial cells.
2. (Canceled) Use of a compound chosen from at least one of manno-oligosaccharides, caseinoglycomacropeptides (CGMP), methyl manno-oligosaccharides, chito oligosaccharides, pectic oligosaccharides, galacto-oligosaccharides (GOS), curdlan (beta 1,3-glucan), sialyl oligosaccharides, isomalto- oligosaccharides, oligogalacturonide, partially hydrolysed guar gum, gentio oligosaccharides, arabino-oligosaccharides, pectin, lactose, lactulose, lactosucrose and long-chain isomalto-oligosaccharides for the manufacture of a nutritional or pharmaceutical composition for the prevention or treatment of acute or chronic pathogen-associated enteric disorders in a mammal, in particular gastroenteritis, ulcerative colitis, or diarrhoeal diseases, or for the prevention or treatment of pathogenic microflora proliferation in a mammal.
3. (Canceled) Use of a compound chosen from at least one of manno-oligosaccharides, caseinoglycomacropeptides (CGMP), methyl manno'oligosaccharides, chito oligosaccharides, pectic oligosaccharides, galacto-oligosaccharides (GOS), curdlan (beta 1,3-glucan), sialyl oligosaccharides, isomalto- oligosaccharides, oligogalacturonide, partially hydrolysed guar gum, gentio oligosaccharides, arabino-oligosaccharides, pectin, lactose, lactulose, lactosucrose and long chain isomalto-oligosaccharides for the inhibition of pathogen adhesion to mammalian cells and/or for preventing, reducing or inhibiting the invasion and infection of mammalian cells, in particular gut and intestinal mammalian cells, by pathogen.
4. (Canceled) A method of preventing and/or treating acute or chronic pathogen- associated, e.g. bacteria-associated, enteric disorders in a mammal, in particular diarrhoeal diseases, gastroenteritis or ulcerative colitis, said method comprising administering to said mammal a therapeutically effective amount of a compound chosen from at least one of manno- oligosaccharides, caseinoglycomacropeptides (CGMP), methyl manno-oligosaccharides, chito oligosaccharides, pectic oligosaccharides, galacto-oligosaccharides (GOS), curdlan (beta-1,3-glucan), sialyl oligosaccharides, pectin, lactose, lactulose, lactosucrose, isomalto- oligosaccharides, oligogalacturonide, partially hydrolysed guar gum, gentio oligosaccharides, arabino-oligosaccharides and long-chain isomalto- oligosaccharides.
5. (Canceled) Use according to any one of claims 1 to 3, or method according to claim 4, wherein the compound is chosen from at least one of manno- oligosaccharides, pectic- ligosaccharides, sialyl-

oligosaccharides, chito- oligosaccharides, caseinoglycomacropeptide (CGMP), galacto- oligosaccharides (GOS), curdlan and partially hydrolysed guar gum.

6. (Canceled) Use or method according to claim 5, wherein the compound is chosen from at least one of caseinoglycomacropeptide (CGMP), chito oligosaccharides, pectic oligosaccharides, sialyl oligosaccharides and curdlan.

7. (Canceled) Use or method according to any one of claims 1 to 5, wherein the manno- oligosaccharide is chosen from at least one of alpha 1-2 manno- oligosaccharide, alpha 1-3 manno-oligosaccharide and alpha 1-6 manno- oligosaccharide.

8. (Canceled) A nutritional or pharmaceutical composition comprising at least one compound chosen from manno-oligosaccharides and/or methyl manno- oligosaccharides, in particular chosen from alpha 1-2 mannobioses, alpha 1-3 mannobioses, alpha 1-6 mannobioses, or methyl alpha manno- oligosaccharides.

9. (Canceled) A nutritional or pharmaceutical composition comprising at least one compound chosen from caseinoglycomacropeptides (CGMP), chito oligosaccharides, pectic oligosaccharides, curdlan (beta-1,3-glucan), sialyl oligosaccharides, isomalto-oligosaccharides, oligogalacturonide, gentio oligosaccharides, arabino-oligosaccharides and long-chain isomalto- oligosaccharides and a nutritionally or pharmaceutically acceptable excipient.

10. (Canceled) A nutritional or pharmaceutical composition according to claim 9 wherein the compound is chosen from at least one of chito oligosaccharides, pectic oligosaccharides, sialyl oligosaccharides and curdlan.

11. (Canceled) A screening method to test the anti-adhesive activity of an oligosaccharide which method comprises a) adding oligosaccharide solution to cell monolayers of the human colonic cell line HT29 in triplicate wells, b) adding an equal volume of bacterial culture, c)washing of the cell layers after 2h at 37°C aerobic, 5% CO₂, d) detaching cell layers with trypsin/EDTA solution, e) enumerating bacteria by plate counting, and f) comparing counts in wells with oligosaccharides to those without.

12. (new) A nutritional or pharmaceutical composition for at least one of: the inhibition of pathogen adhesion to mammalian cells, or for preventing, reducing or inhibiting the invasion and infection of mammalian cells by pathogen, wherein the mammal cells invaded or infected are mammalian gut or intestinal epithelial cells comprising: a compound chosen from at least one of:
manno- oligosaccharides, caseinoglycomacropeptides (CGMP), methyl manno- oligosaccharides, chito oligosaccharides, pectic oligosaccharides, galacto-oligosaccharides (GOS), curdlan (beta 1,3-glucan), sialyl- oligosaccharides, isomalto-oligosaccharides, oligogalacturonide, partially hydrolysed guar gum, gentio-oligosaccharides, arabino- oligosaccharides, pectin, lactose, lactulose, lactosucrose and long-chain isomalto-oligosaccharides.

13. (new) A nutritional or pharmaceutical composition according to claim 12, wherein the compound is chosen from at least one of manno- oligosaccharides, pectic- ligosaccharides, sialyl-oligosaccharides, chito- oligosaccharides, caseinoglycomacropeptide (CGMP), galacto- oligosaccharides (GOS), curdlan and partially hydrolysed guar gum.

14. (new) A nutritional or pharmaceutical composition according to claim 12, wherein the compound is chosen from at least one of caseinoglycomacropeptide (CGMP), chito oligosaccharides, pectic oligosaccharides, sialyl oligosaccharides and curdlan.

15 (new) A nutritional or pharmaceutical composition according to claim 12, wherein the manno-oligosaccharide is chosen from at least one of alpha 1-2 manno- oligosaccharide, alpha 1-3 manno-oligosaccharide and alpha 1-6 manno- oligosaccharide.

16. (new) A nutritional or pharmaceutical composition for the prevention or treatment of acute or chronic pathogen-associated enteric disorders in a mammal, or for the prevention or treatment of pathogenic microflora proliferation in a mammal comprising: a compound chosen from at least one of: manno-oligosaccharides, caseinoglycomacopeptides (CGMP), methyl manno-oligosaccharides, chito oligosaccharides, pectic oligosaccharides, galacto-oligosaccharides (GOS), curdlan (beta 1,3-glucan), sialyl oligosaccharides, isomalto- oligosaccharides, oligogalacturonide, partially hydrolysed guar gum, gentio oligosaccharides, arabino-oligosaccharides, pectin, lactose, lactulose, lactosucrose and long-chain isomalto-oligosaccharides.

17 (new) A nutritional or pharmaceutical composition according to claim 16 wherein said acute or chronic pathogen-associated enteric disorders is gastroenteritis, ulcerative colitis, or diarrhoeal diseases, or a combination thereof.

18. (new) Use of a compound chosen from at least one of manno-oligosaccharides, caseinoglycomacopeptides (CGMP), methyl manno'oligosaccharides, chito oligosaccharides, pectic oligosaccharides, galacto-oligosaccharides (GOS), curdlan (beta 1,3-glucan), sialyl oligosaccharides, isomalto- oligosaccharides, oligogalacturonide, partially hydrolysed guar gum, gentio oligosaccharides, arabino-oligosaccharides, pectin, lactose, lactulose, lactosucrose and long chain isomalto-oligosaccharides for the inhibition of pathogen adhesion to mammalian cells or for preventing, reducing or inhibiting the invasion and infection of mammalian cells, wherein said mammalian cells are those of the gut and intestinal mammalian cells, by pathogen.

19. (new) A method of preventing or treating acute or chronic pathogen- associated, enteric disorders in a mammal, said method comprising administering to said mammal a therapeutically effective amount of a compound chosen from at least one of manno- oligosaccharides, caseinoglycomacopeptides (CGMP), methyl manno-oligosaccharides, chito oligosaccharides, pectic oligosaccharides, galacto-oligosaccharides (GOS), curdlan (beta-1,3-glucan), sialyl oligosaccharides, pectin, lactose, lactulose, lactosucrose, isomalto- oligosaccharides, oligogalacturonide, partially hydrolysed guar gum, gentio oligosaccharides, arabino-oligosaccharides and long-chain isomalto- oligosaccharides.

20 (new) A method according to claim 19 wherein said enteric disorders is gastroenteritis, ulcerative colitis, or diarrhoeal diseases, or a combination thereof.

21. (new) Use A method according to claim 19, wherein the compound is chosen from at least one of manno- oligosaccharides, pectic- ligosaccharides, sialyl-oligosaccharides, chito- oligosaccharides, caseinoglycomacropeptide (CGMP), galacto- oligosaccharides (GOS), curdlan and partially hydrolysed guar gum.

22. (new) A method according to claim 19, wherein the compound is chosen from at least one of caseinoglycomacropeptide (CGMP), chito oligosaccharides, pectic oligosaccharides, sialyl oligosaccharides and curdlan.

23 (new) A method according to claim 19, wherein the manno- oligosaccharide is chosen from at least one of alpha 1-2 manno- oligosaccharide, alpha 1-3 manno-oligosaccharide and alpha 1-6 manno-oligosaccharide.

24. (new) A nutritional or pharmaceutical composition comprising at least one compound chosen from manno-oligosaccharides and/or methyl manno- oligosaccharides, in particular chosen from alpha 1-2 mannobioses, alpha 1-3 mannobioses, alpha 1-6 mannobioses, or methyl alpha manno- oligosaccharides.

25. (new) A nutritional or pharmaceutical composition comprising at least one compound chosen from caseinoglycomacropeptides (CGMP), chito oligosaccharides, pectic oligosaccharides, curdlan (beta-1,3-glucan), sialyl oligosaccharides, isomalto-oligosaccharides, oligogalacturonide, gentio oligosaccharides, arabino-oligosaccharides and long-chain isomalto- oligosaccharides and a nutritionally or pharmaceutically acceptable excipient.

26. (new) A nutritional or pharmaceutical composition according to claim 25 wherein the compound is chosen from at least one of chito oligosaccharides, pectic oligosaccharides, sialyl oligosaccharides and curdlan.

26. (new) A screening method to test the anti-adhesive activity of an oligosaccharide which method comprises:

- a) adding oligosaccharide solution to cell monolayers of the human colonic cell line HT29 in triplicate wells,
- b) adding an equal volume of bacterial culture,
- c) washing of the cell layers after 2h at 37°C aerobic, 5% CO₂,
- d) detaching cell layers with trypsin/EDTA solution,
- e) enumerating bacteria by plate counting, and
- f) comparing counts in wells with oligosaccharides to those without.

27. (new) Use of a compound for the manufacture of a nutritional or pharmaceutical composition for the inhibition of pathogen adhesion to mammalian cells, or for preventing, reducing or inhibiting the invasion and infection of mammalian cells by pathogen, wherein said mammalian cells are mammalian gut or intestinal epithelial cells, comprising: manno- oligosaccharides, caseinoglycomacropeptides (CGMP), methyl manno- oligosaccharides, chito oligosaccharides, pectic oligosaccharides, galacto- oligosaccharides (GOS), curdlan (beta 1,3-glucan), sialyl- oligosaccharides, isomalto-oligosaccharides, oligogalacturonide, partially hydrolysed guar gum, gentio-oligosaccharides, arabino- oligosaccharides, pectin, lactose, lactulose, lactosucrose and long-chain isomalto- oligosaccharides, or a combination thereof.

28. (new) Use of a compound for the manufacture of a nutritional or pharmaceutical composition for the prevention or treatment of acute or chronic pathogen-associated or for the prevention or treatment of pathogenic microflora proliferation in a mammal chosen comprising manno-oligosaccharides, caseinoglycomacropeptides (CGMP), methyl manno-oligosaccharides, chito oligosaccharides, pectic oligosaccharides, galacto-oligosaccharides (GOS), curdlan (beta 1,3-glucan), sialyl oligosaccharides, isomalto-oligosaccharides, oligogalacturonide, partially hydrolysed guar gum, gentio oligosaccharides, arabino-oligosaccharides, pectin, lactose, lactulose, lactosucrose and long-chain isomalto- oligosaccharides or a combination thereof.

29. A use according to claim 28 wherein said enteric disorders are gastroenteritis, ulcerative colitis, or diarrhoeal diseases,